1. Cho WS, Kim JE, Kim CH, et al: Long-term outcomes after combined revascularization surgery in adult moyamoya disease. Stroke 2014;45: 3025-3031
2. Deng X, Gao F, Zhang D, et al: Direct versus indirect bypasses for adult ischemic-type moyamoya disease: a propensity score-matched analysis. J Neurosurg 2018;128:1785-1791
3. Fujimura M and Tominaga T: Lessons learned from moyamoya disease: Outcome of direct/indirect revascularization surgery for 150 affected hemispheres. Neurol Med Chir (Tokyo) 2012;52:327-332
4. Houkin K, Ishikawa T, Yoshimoto T, et al: Direct and indirect revascularization for moyamoya disease: surgical techniques and peri-operative complications. Clin Neurol Neurosurg 1997;99 Suppl2:S142-145
5. Jeon JP, Kim JE, Cho WS, et al: Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J Neurosurg 2018;128:793-799
6. Kim H, Jang DK, Han YM, et al: Direct versus indirect bypass in adult moyamoya angiopathy with symptom or hemodynamic instability: a meta-analysis of comparative study. World Neurosurg 2016;94:273-284
7. Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant for Research on Measures for Intractable Diseases: Guidelines for diagnosis and treatment of moyamoya disease (Spontaneous Occlusion of the Circle of Willis). Neurol Med Chir (Tokyo) 2012;52:245-266
8. Tominaga T, Suzuki N, Miyamoto S, et al: Recommendations for the management of Moyamoya disease: A statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) [2nd Edition]. Surg Cereb Stroke 2018 (Jpn);46:1-24
9. Miyamoto S, Yoshimoto T, Hashimoto N, et al: Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke 2014;45:1415-1421
10. Takahashi JC, Funaki T, Houkin K, et al: Significance of the Hemorrhagic Site for Recurrent Bleeding: Prespecified Analysis in the Japan Adult Moyamoya Trial. Stroke 2016;47:37-43
11. Fujimura M, Kaneta T, Mugikura S, et al: Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease. Surg Neurol 2007;67:273-282
12. Fujimura M, Mugikura S, Kaneta T, et al: Incidence and risk factors for symptomatic cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease. Surg Neurol 2009;71:442-447
13. Fujimura M, Shimizu H, Mugikura S, et al: Delayed intracerebral hemorrhage after superficial temporal artery-middle cerebral artery anastomosis in a patient with moyamoya disease: possible involvement of cerebral hyperperfusion and increased vascular permeability. Surg Neurol 2009;71:223-227
14. Fujimura M, Shimizu H, Inoue T, et al: Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after extracranial-intracranial bypass for moyamoya disease: Comparative study with non-moyamoya patients using n-isopropyl-p-[(123)i]iodoamphetamine single-photon emission computed tomography. Neurosurgery 2011;68:957-964
15. Kim JE, Oh CW, Kwon OK, et al: Transient hyperperfusion after superficial temporal artery/middle cerebral artery bypass surgery as a possible cause of postoperative transient neurological deterioration. Cerebrovasc Dis 2008;25:580-586
16. Fujimura M, Inoue T, Shimizu H, et al: Efficacy of prophylactic blood pressure lowering according to a standardized postoperative management protocol to prevent symptomatic cerebral hyperperfusion after direct revascularization surgery for moyamoya disease. Cerebrovasc Dis 2012;33:436-445
17. Fujimura M, Niizuma K, Inoue T, et al: Minocycline prevents focal neurologic deterioration due to cerebral hyperperfusion after extracranial-intracranial bypass for moyamoya disease. Neurosurgery 2014;74:163-170
18. Uchino H, Nakayama N, Kazumata K, et al: Edaravone Reduces Hyperperfusion-Related Neurological Deficits in Adult Moyamoya Disease: Historical Control Study. Stroke 2016;47:1930-1932
19. Kazumata K, Uchino H, Tokairin K, et al: Cerebral hyperperfusion syndrome after revascularization surgery in moyamoya disease: Region-symptom mapping and estimating a critical threshold. World Neurosurg 2018;114:e388-e395
20. Park W, Park ES, Lee S, et al: Intracranial hemorrhage after superficial temporal artery-middle cerebral artery direct anastomosis for adults with moyamoya disease. World Neurosurg 2018;119:e774-e782
21. Tokairin K, Kazumata K, Uchino H, et al: Postoperative intracerebral hemorrhage after combined revascularization surgery in moyamoya disease: Profiles and clinical associations. World Neurosurg 2018;120:e593-e600
22. Fujimura M and Tominaga T: Current status of revascularization surgery for moyamoya disease: special consideration for its ‘internal carotid-external carotid (IC-EC) conversion’ as the physiological reorganization system. Tohoku J Exp Med 2015;236:45-53
23. Fujimura M, Niizuma K, Endo H, et al: Quantitative analysis of early postoperative cerebral blood flow contributes to the prediction and diagnosis of cerebral hyperperfusion syndrome after revascularization surgery for moyamoya disease. Neurol Res 2015;37(2):131-138
24. Tashiro R, Fujimura M, Kameyama M, et al: Incidence and risk factors of the watershed shift phenomenon after superficial temporal artery-middle cerebral artery anastomosis for adult moyamoya disease. Cerebrovasc Dis 2019;47:178-187
25. Fujimura M and Tominaga T: Significance of cerebral blood flow analysis in the acute stage after revascularization surgery for moyamoya disease. Neurol Med Chir (Tokyo) 2015;55:775-781
26. Ishikawa T, Yamaguchi K, Kawashima A, et al: Predicting the occurrence of hemorrhagic cerebral hyperperfusion syndrome using regional cerebral blood flow after direct bypass surgery in patients with moyamoya disease. World Neurosurg 2018;119:e750-e756.
27. Hwang JW, Yang HM, Lee H, et al: Predictive factors of symptomatic cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in adult patients with moyamoya disease. Br J Anaesth 2013;110:773-779
28. Uchino H, Kuroda S, Hirata K, et al: Predictors and clinical features of postoperative hyperperfusion after revascularization for moyamoya disease: a serial single photon emission CT/positron emission tomography study. Stroke 2012;43:2610-2616
29. Fujimura M, Gasche Y, Morita-Fujimura Y, et al: Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999;842:92-100
30. Narducci A, Yasuyuki K, Onken J, et al: In vivo demonstration of blood-brain barrier impairment in moyamoya disease. Acta Neurochir (Wien) 2019;161:371-378
31. Fujimura M, Watanabe M, Narisawa A, et al: Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease. Surg Neurol 2009;72:476-480
32. Kawamata T, Oakada Y, Kawashima A, et al: Postcarotid endartectomy cerebral hyperperfusion can be prevented by minimizing intraoperative cerebral ischemia and strict postoperative blood pressure control under continuous sedation. Neurosurgery 2009;64:447-453
33. Nomura S, Yamaguchi K, Ishikawa T, et al: Factors of delayed hyperperfusion and the importance of repeated cerebral blood evaluation for hyperperfusion after direct bypass for moyamoya disease. World Neurosurg 2018;118:e468-e472
34. Oshima T, Karasawa F, Satoh T: Effects of Propofol on cerebral blood flow and the metabolic rate of oxygen in humans. Acta Anaesthesiol Scand 2002;46:831-835
35. Hayashi T, Shirane R, Fujimura M, et al: Postoperative neurological deterioration in pediatric moyamoya disease: watershed shift and hyperperfusion. J Neurosurg Pediatr 2010;6:73-81
論文の公開元へ
